Showing results (51-60 of 536) with videos related to
Sort By:
Pageof 54
BJU International|January 26, 2005
Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?Claartje Gosselaar, Monique J Roobol, Fritz H SchröderAnnual Review of Medicine|November 8, 2011
Screening for prostate cancer: early detection or overdetection?Andrew J Vickers, Monique J Roobol, Hans LiljaThe Biochemical Journal|February 3, 2011
ATR (ataxia telangiectasia mutated- and Rad3-related kinase) is activated by mild hypothermia in mammalian cells and subsequently activates p53Anne Roobol, Jo Roobol, Martin J Carden, et al.Metabolic Engineering|February 17, 2020
Engineered transient and stable overexpression of translation factors eIF3i and eIF3c in CHOK1 and HEK293 cells gives enhanced cell growth associated with increased c-Myc expression and increased recombinant protein synthesisAnne Roobol, Joanne Roobol, Matthew E Smith, et al.International Journal of Molecular Sciences|April 17, 2019
Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer DiagnosisDaniël F Osses, Monique J Roobol, Ivo G SchootsEuropean Journal of Biochemistry|March 1, 1996
Degradation of the light-stress protein is mediated by an ATP-independent, serine-type protease under low-light conditionsI Adamska, M Lindahl, M Roobol-Bóza, et al.BJU International|February 27, 2004
Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands)M J Roobol, W J Kirkels, F H SchröderBritish Journal of Cancer|June 1, 1984
5-fluorouracil and 5-fluoro-2'-deoxyuridine follow different metabolic pathways in the induction of cell lethality in L1210 leukaemiaC Roobol, G B De Dobbeleer, J L BernheimThe Prostate|December 29, 2006
The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC)M J Roobol, M Zappa, L Määttänen, et al.European Urology|February 12, 2008
Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPCFritz H Schröder, Chris H Bangma, Monique J RoobolPageof 54